Structure–activity relationships of triazolopyridine oxazole p38 inhibitors: Identification of candidates for clinical development

The synthesis, structure–activity relationship, in vivo activity, and metabolic profile for a series of triazolopyridine-oxazole based p38 inhibitors are described. The deficiencies of the lead structure in the series, CP-808844, were overcome by changes to the C4 aryl group and the triazole side-chain culminating in the identification of several potential clinical candidates.

Figure optionsDownload as PowerPoint slide